4th Quarter - Report — BROWN RUDNICK LLP for APOTEX CORPORATION (2014)

Firm

BROWN RUDNICK LLP

Client

APOTEX CORPORATION

Income

$50,000

Expenses

—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 5748 and S. 2948 - The Medicaid Generic Drug Price Fairness Act; Issues relating to generic drug use in the Medicare Part D program

Lobbyist	Covered position, as disclosed
LISA LAYMAN	SPA, Sen. Stabenow (05-07)
HENRY W MENN	CoS, Sen. Bob Graham (01 - 04)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2948 (113th), H.R. 5748 (113th)

Pharmacy PHA

H.R. 5657 - The Fair Access for Safe and Effective Generics Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)

Lobbyist	Covered position, as disclosed
LISA LAYMAN	SPA, Sen. Stabenow (05-07)
HENRY W MENN	CoS, Sen. Bob Graham (01 - 04)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5657 (113th)

Health Issues HCR

Implementation of the Biologics Price Competition and Innovation Act (BPCIA); H.R. 3116 - Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act of 2013

Lobbyist	Covered position, as disclosed
LISA LAYMAN	SPA, Sen. Stabenow (05-07)
HENRY W MENN	CoS, Sen. Bob Graham (01 - 04)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3116 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.